Remix Therapeutics

Reprogramming RNA to transform patients’ lives.

Remix Therapeutics is advancing a new class of therapeutics by modulating RNA processing with small molecules.

Learn More

Current Beat

Mar | 19 | 2026
Press Release
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor Adenoid Cystic Carcinoma   WATERTOWN, Mass., March 19, 2026 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing […]
Read More
May | 19 | 2025
News
REMastering Drug Discovery: Harnessing RNA Processing to Tackle 'Undruggable' Proteins
My dad passed away when he was just fifty-six from acute myeloid leukemia (AML). Even with all the progress we’ve made treating cancer, it’s one of those diseases that still leaves too many people and families with too few options. The outlook can be particularly tough depending on factors like age, other health issues, and […]
Read More
Apr | 15 | 2025
Press Release
Remix Therapeutics™ Appoints Linda C. Bain to Board of Directors
Watertown, Mass. (April 15, 2025) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of life science executive, Linda C. Bain, to its Board of Directors. Ms. Bain is a Venture Partner at Atlas Venture and currently […]
Read More
Mar | 31 | 2025
Press Release
Remix Therapeutics™ to Present at Stifel 2025 Virtual Targeted Oncology Forum
Watertown, Mass. (March 31, 2025) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on […]
Read More

REMaster™ Drug
Discovery Platform

Our proprietary platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease drivers.
Learn More

mRNA Degrader
REM-422

REM-422 is an investigational first-in-class orally available, small molecule mRNA degrader that targets the pre-mRNA of MYB, a previously undruggable transcription factor known to drive a diverse range of diseases.
Learn More

It's Sound Science

About Us
Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
About Us

Contact

General Inquiry